Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Disease    save search

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
Published: 2023-12-03 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $1.66 -8.29% 0.0% 24K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

ath434 disease positive parkinson’s therapeutics
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 19:00) - prnewswire.com
SNYNF | $94.0 1.34% 1.34% 860 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVSEF | $97.95 1.48% 2.98% 100 twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
BHC | $7.36 3.08% 0.0% 1.8M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
BIIB | $234.64 0.24% 0.26% 570K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
BCLI | $0.26 -6.81% -7.31% 3.7M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
VTRS | $9.37 2.07% 1.92% 6.4M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
NVS | $98.13 0.24% -0.16% 1.2M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

disease companies health therapeutics market
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
SNGX | $0.73 75.73% -5.49% 7M twitter stocktwits trandingview |
Health Technology
| | O: 32.76% H: 0.0% C: 0.0%

fda disease treatment clearance trial
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | $94.0 1.34% 1.34% 860 twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 0.0% C: 0.0%
TEVA | $9.71 -1.12% 0.0% 6.2M twitter stocktwits trandingview |
Health Technology
| | O: -0.52% H: 3.73% C: 1.87%
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: -1.09% H: 0.0% C: 0.0%

disease treatment collaboration teva deal
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GH | $26.33 4.61% 0.61% 1.1M twitter stocktwits trandingview |
Health Services
| | O: 1.51% H: 3.92% C: -1.29%

disease breast health symposium biomarker cancer therapy
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $6.19 1.81% 2.01% 900K twitter stocktwits trandingview |
Manufacturing
| | O: 8.68% H: 0.0% C: 0.0%

fda rare drug disease program
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
BIVI P | $1.68 -6.67% -6.82% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: -70.4% H: 0.0% C: 0.0%

ne3107 disease alzheimer’s trial
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
CERE | $26.0 0.27% -2.0% 1.6M twitter stocktwits trandingview |
Finance
| | O: -0.08% H: 5.19% C: 1.2%

disease parkinson’s therapeutics
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
QURE | $7.14 5.31% 4.84% 740K twitter stocktwits trandingview |
Health Technology
| | O: 3.25% H: 4.58% C: -2.58%

amt-191 fda drug disease clearance application therapy
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
Published: 2023-11-28 (Crawled : 14:00) - globenewswire.com
STXS | $1.77 7.27% 0.0% 220K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

disease health heart technology
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ATHA | $1.51 4.86% 4.64% 160K twitter stocktwits trandingview |
Health Technology
| | O: -2.61% H: 0.0% C: 0.0%

pharma disease symposium presentation international
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27 (Crawled : 23:00) - biospace.com/
ALDX | $2.86 3.25% 0.35% 910K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

reproxalap drug disease food treatment eye application therapeutics response
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD G | $22.6 1.44% 0.0% 1.2M twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

acp-204 disease alzheimer’s treatment pharmaceuticals trial
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
INMB | $9.61 1.69% -1.67% 57K twitter stocktwits trandingview |
Health Technology
| | O: 2.0% H: 5.24% C: 2.29%

disease alzheimer’s authorization trial
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ICAD | $1.77 9.94% -1.13% 220K twitter stocktwits trandingview |
Technology Services
| | O: 0.38% H: 0.0% C: 0.0%

reveal disease breast year cancer risk heart
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
ANVS | $8.49 1.88% 240K twitter stocktwits trandingview |
Health Technology
| | O: 2.56% H: 17.65% C: 8.68%

disease alzheimer’s
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Published: 2023-11-27 (Crawled : 12:30) - globenewswire.com
SEOVF | $0.518 -2.23% 39.11% 100K twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

fda rare drug disease program
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 1.04% H: 0.17% C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K twitter stocktwits trandingview |
Health Technology
| | O: -0.03% H: 0.37% C: -0.49%

dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNY | $46.72 -0.06% -0.06% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 1.04% H: 0.17% C: 0.11%
REGN | $814.86 -1.09% 0.31% 560K twitter stocktwits trandingview |
Health Technology
| | O: -0.03% H: 0.37% C: -0.49%

dupixent fda disease approved positive copd potential submission
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Published: 2023-11-26 (Crawled : 00:00) - globenewswire.com
MESO | $1.36 -1.45% -2.94% 0 twitter stocktwits trandingview |
Health Technology
| | O: 4.21% H: 2.94% C: 0.74%

rare drug disease treatment heart
Gainers vs Losers
77% 23%

Top 10 Gainers
ID 4 | $0.077 -9.41% 25.97% 420K twitter stocktwits trandingview |
Finance

BKKT 4 | $1.88 25.33% 14.89% 4.8M twitter stocktwits trandingview |

MGLD | $1.03 7.77% 14K twitter stocktwits trandingview |
Manufacturing

CZOO | $0.4316 -6.52% 6.7% 65K twitter stocktwits trandingview |

SATX | $0.4226 -1.72% 6.48% 29K twitter stocktwits trandingview |
n/a

CCJ | $45.4 -1.13% 4.6% 3.9M twitter stocktwits trandingview |
Non-Energy Minerals

AUMN | $0.562 0.34% 4.5% 360K twitter stocktwits trandingview |
Non-Energy Minerals

JBL | $116.91 1.38% 4.3% 2M twitter stocktwits trandingview |
Electronic Technology

SAIC 4 | $119.92 2.14% 4.24% 460K twitter stocktwits trandingview |
Technology Services

CULP 4 | $5.06 -0.59% 3.95% 29K twitter stocktwits trandingview |
Process Industries


Your saved searches
Save your searches and get alerts when important news are released.